We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty Sanofi adds over €1 billion for...
Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands...
Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19...
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower...
Communiqué de presse : Assemblée Générale Annuelle du 30 avril 2024 Assemblée Générale Annuelle du 30 avril 2024 Approbation des comptes sociaux et des comptes consolidés de l’exercice...
Communiqué de presse : Sanofi réitère ses objectifs financiers pour 2024, après une forte croissance de 7% portée par les lancements ...
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris...
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal...
Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en...
Sanofi: Information concerning the total number of voting rights and shares - March 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.65 | 0.713971880492 | 91.04 | 94.47 | 90.48 | 1474190 | 93.13153396 | DE |
4 | 4.6 | 5.28189229533 | 87.09 | 94.47 | 85.07 | 1535400 | 90.47609937 | DE |
12 | 5.63 | 6.5419474785 | 86.06 | 94.47 | 85.07 | 1414296 | 89.07211328 | DE |
26 | 6.1 | 7.12700081785 | 85.59 | 96.5 | 83.28 | 1426530 | 88.89212108 | DE |
52 | -8.28 | -8.28248474542 | 99.97 | 104.32 | 80.6 | 1439333 | 92.64283423 | DE |
156 | 4.84 | 5.57282671272 | 86.85 | 106.66 | 76.45 | 1796927 | 91.13231669 | DE |
260 | 18.45 | 25.1911523758 | 73.24 | 106.66 | 67.65 | 2042981 | 87.44926888 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions